Baudax Bio’s Anjeso Receives the US FDA’s Approval to Manage Moderate to Severe Pain

 Baudax Bio’s Anjeso Receives the US FDA’s Approval to Manage Moderate to Severe Pain

Shots:

  • The approval of Anjeso is based on two P-III studies assessing Anjeso (30mg, bolus injection) following Major Surgery and Abdominoplasty Surgery vs PBO in ratio (1:1) in 932 patients
  • The study demonstrated well tolerated results, also achieved 15 of the 19 secondary endpoints, plus statistically significant differences in SPID6, SPID12, SPID24, SPID24-48 with no serious adverse events
  • Anjeso (meloxicam) injection is a long-acting, preferential COX-2 inhibitor that possess analgesic, anti-inflammatory and antipyretic activities also approved by the US FDA in Feb,2020 for moderate to severe pain, alone or in combination with other non-NSAID analgesics

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post